Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the dual GLP-1/glucagon receptor agonist’s reach far beyond its most advanced indications of metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Key Takeaways
- Altimmune made a case for its dual GLP-1/glucagon receptor agonist pemvidutide in multiple diseases at an investor day, including MASH and obesity.
The company described the drug as Phase III-ready in obesity, soon to report Phase IIb histology data in MASH and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?